Matthew Samra, D.O Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 37 Nautilus Dr, Manahawkin, NJ 08050 Phone: 866-356-9286 Fax: 609-978-1377 |
Michael Delrosario, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 44 Nautilus Dr Ste B, Manahawkin, NJ 08050 Phone: 609-978-3390 Fax: 609-978-3190 |
Mr. Floro G Guerrero, M.D Surgery Medicare: Medicare Enrolled Practice Location: 24 Nautilus Dr, Manahawkin, NJ 08050 Phone: 609-597-6072 Fax: 609-597-5255 |
Sergey Grachev, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 115 E Bay Ave, Manahawkin, NJ 08050 Phone: 609-597-9477 Fax: 609-597-9877 |
Carey Penrod, D.O. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1364 Route 72 W, Suite 5, Manahawkin, NJ 08050 Phone: 609-978-0778 Fax: 609-978-1377 |
Dr. James Preston Nangeroni, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 1100 Route 72 W Ste 303, Manahawkin, NJ 08050 Phone: 609-978-3325 |
Dr. Nole E Almendras, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 585 Us Highway Route 72 E, Manahawkin, NJ 08050 Phone: 609-597-7077 Fax: 609-978-8455 |
Jonathan M Reich, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1100 Route 72 W, Suite 303, Manahawkin, NJ 08050 Phone: 609-978-3325 Fax: 609-978-3123 |
Gary P Lengel, MD Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 1100 Route 72 W, Suite 307, Manahawkin, NJ 08050 Phone: 609-625-8000 Fax: 609-978-8941 |
Arthur J Demarsico, D.O. Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 37 Nautilus Dr, Manahawkin, NJ 08050 Phone: 866-356-9286 Fax: 609-978-1377 |
Jeffrey Hager, D.O. Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 37 Nautilus Dr, Manahawkin, NJ 08050 Phone: 609-978-0778 Fax: 609-978-1377 |
News Archive
New insight into the function of a gene important in the suppression of cancer is published today. Researchers at the National University of Ireland Galway have shown that the TP53 gene has even greater anti-cancer activity than previously thought.
Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA).
Ashkenazi Jewish women are known to have a predisposition to the inherited breast cancers BRCA1 and BRCA2, but currently genetic testing in this group is limited to women affected by breast and ovarian cancers and those who are unaffected but have a family history of the disease.
Repligen Corporation today announced that the Company has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich's ataxia from the Muscular Dystrophy Association (MDA).
› Verified 6 days ago